Skip to content

Frontline
AI News
Jobs
Sectors

Frontline
AI News
Jobs
Sign in

Live sectors

Coming soon

Loading

Frontline
AI News
Jobs
Sectors

Frontline
AI News
Jobs
Sign in

Live sectors

Coming soon

Loading

Companies
KPIs
Latest News
Videos
Talent
Catalysts
Venture Stages
Valuations
Funding
Bottlenecks
Theses
Top 10
Books
HQ Map

Frontline
AI News
Jobs
Sectors

- Blockchain / Crypto
- Cloud & Edge Computing
- Cybersecurity
- Data Infrastructure
- Digital Identity
- Payments & Financial Infrastructure

Frontline
AI News
Jobs
Sign in

Live sectors

Coming soon

Brain-Computer Interfaces

Brain-Computer Interfaces

Today's FOBI Editorial

Real BCI value lies in closed-loop restoration, not open-ended neural interface scale.

Read today's Editorial →

For subscribers

Subscribe for the full sector dashboard

Including The tracked-40 roster, Funding timeline, Valuations, Catalyst calendar, Latest news + videos, Talent moves, and Patent activity.

Already subscribed?

Editorial analysis, not financial advice.

Theme

Send feedback

Goes straight to my inbox. No auto-replies, no tickets.

What's this about?

General feedbackSomething's brokenFeature ideaContent / data issue

Feedback

Email (optional — only if you want a reply)

Website

Reviewed weekly.

More▾

FAQ
What's new
Disclosures
Terms
Privacy
Usage policy

© 2026 fobi

Editorial analysis, not financial advice.·FAQ·What’s new

Companies

All subsectors
Assistive BCI Devices
Endovascular BCI
Invasive Cortical Implants
Neuromodulation & Stimulation
Next-Gen Electrodes & Materials
Non-Invasive Clinical EEG
Non-Invasive Consumer EEG
Non-Invasive Neuroimaging
Spinal & Peripheral Interfaces
Vision & Sensory Prosthetics

All statuses
Private
Public

Relevancy
Total raised
Latest round
Name

Science Corporation

Develops the Science Eye, a retinal implant to restore vision, and other neurotechnology platforms led by former Neuralink president.

Vision & Sensory Prosthetics · Series C $230M

Vision & Sensory Prosthetics

Offers EEG-based brain-sensing headbands for education, focus training, prosthetic control, and wellness applications.

Non-Invasive Consumer EEG · Series B+ $286M

Non-Invasive Consumer EEG

OpenAI-backed research lab building non-invasive, high-bandwidth brain-computer interfaces that read and write to neurons using molecules and ultrasound instead of implanted electrodes.

Non-Invasive Neuroimaging · Seed $252M

Non-Invasive Neuroimaging

Delivers a motor neuroprosthesis via the jugular vein into brain blood vessels, avoiding open brain surgery.

Endovascular BCI · Series D $200M

Endovascular BCI

Develops the Evoke closed-loop spinal cord stimulation system, the first SCS device that senses the spinal cord's ECAP response and adjusts therapy on every pulse.

Spinal & Peripheral Interfaces · IPO $150M

Spinal & Peripheral Interfaces

Develops soft, flexible neural electrode arrays designed to minimize scarring and improve long-term biocompatibility in brain implants.

Next-Gen Electrodes & Materials · Series A $55M

Next-Gen Electrodes & Materials

Embeds EEG sensors into everyday headphones to track focus, attention, and cognitive state for productivity and wellness.

Non-Invasive Consumer EEG · Series A $35M

Non-Invasive Consumer EEG

Develops in-ear EEG biosensors for continuous brain activity monitoring in wearable form-factors.

Non-Invasive Consumer EEG · Series A $16M

Non-Invasive Consumer EEG

Designs miniaturized, wireless neural implants with on-board AI processing to decode brain signals locally and reduce data bandwidth requirements.

Invasive Cortical Implants · Seed $10M

Invasive Cortical Implants

Develops high-bandwidth implantable brain-machine interfaces with thousands of electrode channels for paralysis and neurological conditions.

Invasive Cortical Implants · Series E $650M

Invasive Cortical Implants

Precision Neuroscience

Develops a flexible, thin-film electrode array placed on the brain surface to enable high-resolution neural recording with minimally-invasive placement.

Invasive Cortical Implants · Series C $102M

Invasive Cortical Implants

Provides virtual-reality and brain-sensing platforms for stroke rehabilitation and neurological recovery, combining VR with EEG-based neurofeedback.

Non-Invasive Clinical EEG · Growth $125M

Non-Invasive Clinical EEG

INBRAIN Neuroelectronics

Engineers graphene-based neural interfaces for high-resolution, biocompatible brain recording and stimulation.

Next-Gen Electrodes & Materials · Series B $50M

Next-Gen Electrodes & Materials

Blackrock Neurotech

Manufactures the Utah Array and other electrode systems used in academic BCI research and clinical trials for over a decade.

Invasive Cortical Implants · Acquired $200M

Invasive Cortical Implants

Develops spinal cord stimulation platforms to restore movement and function in patients with spinal cord injury.

Spinal & Peripheral Interfaces · IPO $89.6M

Spinal & Peripheral Interfaces

Offers a rapid-deployment EEG system with AI-powered seizure detection for emergency and ICU settings.

Non-Invasive Clinical EEG · Market cap $679.9M

Non-Invasive Clinical EEG

Develops peripheral nerve interfaces and implantable devices for prosthetic control and sensory feedback.

Spinal & Peripheral Interfaces · Series A $19M

Spinal & Peripheral Interfaces

Motif Neurotech

Develops magnetoelectric neural stimulation technology for non-invasive, deep-brain modulation targeting psychiatric and neurological disorders.

Neuromodulation & Stimulation · Series A $18.8M

Neuromodulation & Stimulation

Forest Neurotech

Forest Neurotech is developing an ultrasound-based brain-computer interface for whole-brain imaging and neuromodulation, aiming to read from and stimulate deep brain structures less invasively than electrode implants.

Next-Gen Electrodes & Materials · Series A $14M

Next-Gen Electrodes & Materials

Builds a wearable headband that uses real-time EEG and acoustic stimulation to accelerate sleep onset and improve sleep quality.

Non-Invasive Consumer EEG · Seed $12M

Non-Invasive Consumer EEG

Produces wearable time-domain functional near-infrared spectroscopy headsets for brain activity measurement in research and commercial settings.

Non-Invasive Neuroimaging · Series C $53M

Non-Invasive Neuroimaging

Builds very-high-density cortical implants targeting tens of thousands of electrodes for speech and communication restoration.

Invasive Cortical Implants · Series A $33M

Invasive Cortical Implants

Builds the Crown, a wearable EEG headset with real-time brain-computer interface software for focus, meditation, and app control.

Non-Invasive Consumer EEG · Series A $5.0M

Non-Invasive Consumer EEG

MIT Media Lab spinout building the MouthPad^, a custom-fit intraoral touchpad that lets people control phones and computers hands-free with tongue and head gestures.

Assistive BCI Devices · Seed $4M

Assistive BCI Devices

Develops non-invasive transcranial electrical stimulation and EEG systems for research and clinical applications in epilepsy and neurorehabilitation.

Neuromodulation & Stimulation · Series A $17.5M

Neuromodulation & Stimulation

Produces augmented-reality headsets with integrated EEG for non-verbal communication and assistive technology for patients with speech and motor impairments.

Assistive BCI Devices · Seed $1.8M

Assistive BCI Devices

Provides AI-powered software that interprets brain and body signals from wearable sensors for emotional and cognitive state detection.

Non-Invasive Consumer EEG · Series A $10M

Non-Invasive Consumer EEG

Flow Neuroscience

Produces a transcranial direct current stimulation headset for at-home treatment of depression, combined with behavioral therapy.

Neuromodulation & Stimulation · Series A $9.3M

Neuromodulation & Stimulation

Develops the RNS System, a responsive neurostimulation device that detects and treats epileptic seizures in real time.

Neuromodulation & Stimulation · Market cap $512.1M

Neuromodulation & Stimulation

Manufactures wireless EEG headsets and software for research, education, and consumer brain-computer interface applications.

Non-Invasive Consumer EEG · Seed $3.9M

Non-Invasive Consumer EEG

Provides open-source EEG, EMG, and ECG biosensing hardware and software for researchers and developers building BCI applications.

Non-Invasive Consumer EEG · Seed $1.8M

Non-Invasive Consumer EEG

Develops smart glasses with integrated EEG sensors for cognitive state monitoring and accessibility applications.

Non-Invasive Consumer EEG · Seed

Non-Invasive Consumer EEG

Reads and modulates the vagus nerve to treat chronic inflammatory diseases using implantable neural interfaces.

Spinal & Peripheral Interfaces · Series A

Spinal & Peripheral Interfaces

Galvani Bioelectronics

Joint venture between GSK and Verily developing bioelectronic medicines that modulate peripheral nerves for chronic disease treatment.

Spinal & Peripheral Interfaces · Series A

Spinal & Peripheral Interfaces

Manufactures research-grade neural recording systems and microelectrode arrays for preclinical and clinical BCI applications.

Invasive Cortical Implants

Invasive Cortical Implants

Research organization developing NeuroLife, a BCI system that bypasses spinal cord injury to restore hand and arm movement via cortical recording and muscle stimulation.

Invasive Cortical Implants

Invasive Cortical Implants

g.tec medical engineering

Manufactures clinical-grade EEG and BCI systems for research, rehabilitation, and assistive technology applications.

Non-Invasive Clinical EEG

Non-Invasive Clinical EEG

Boston Scientific

Provides spinal cord stimulation and deep brain stimulation devices for chronic pain, Parkinson's disease, and essential tremor.

Neuromodulation & Stimulation · Market cap $69.7B

Neuromodulation & Stimulation

Manufactures deep brain stimulation, spinal cord stimulation, and other implantable neuromodulation devices for Parkinson's, pain, and movement disorders.

Neuromodulation & Stimulation · Market cap $104.4B

Neuromodulation & Stimulation

Offers spinal cord stimulation, dorsal root ganglion stimulation, and deep brain stimulation systems for chronic pain and movement disorders.

Neuromodulation & Stimulation · Market cap $157.8B

Neuromodulation & Stimulation

No roster changes this week. The roster is re-evaluated quarterly; read the methodology in the disclosures.

KPIs

Total funding YTD

$0

across 4 rounds

Companies tracked

0

10 countries

Largest round YTD

$0

BrainCo · Series B+

Median round YTD

$0

across 4 rounds

News volume · 7d

0

new window

Latest News

1dDemopositive
The Download: the first brain implant power user and South Korea’s AI obsession
Casey Harrell, an ALS patient with a brain implant, becomes the first power user of a speech BCI after three years of independent operation, regaining communication and job capability.
MIT Technology Review
1dResearchpositive
Adaptive Deep Brain Stimulation Fixes Parkinson’s Walking Gait

Videos

View all 277 →

Talent Moves

Apr 28, 2026
Adam Molnar
Co-founder
From
Co-founder
at Neurable
To
Chief Operating Officer
at Neurable
Business Wire
Apr 28, 2026
Reid Van Gorder
Finance Executive
From
Prior finance leadership role
at Undisclosed
To
Chief Financial Officer
at Neurable
Business Wire
Jan 23, 2026
Ali Kiboro
CFO
From
Chief Financial Officer
at AliveDx (formerly Quotient Limited)
To
Chief Financial Officer
at ONWARD Medical
GlobeNewswire
Aug 19, 2025
Andy Rasdal
Board Member
From
Board Director (former DexCom CEO)
at Synchron (Board)
To
Chief of Staff
at Synchron
Business Wire
Aug 19, 2025
Mark Brister
Senior R&D Executive
From
R&D Leadership (38 years, 450+ patents)
at Obalon Therapeutics / Medtronic / DexCom
To
VP of R&D
at Synchron
Business Wire
Jun 11, 2025
Vanessa Tolosa
Hardware Research Manager
From
Hardware Research Manager (formerly Neuralink co-founder & Director of Neural Interfaces)
at Meta Reality Labs
To
SVP of Research and Development
at Precision Neuroscience
GlobeNewswire
Jun 11, 2025
Vivek Pinto
Division Director, CDRH
From
Division Director, Center for Devices and Radiological Health
at U.S. Food and Drug Administration
To
Director of Medical Affairs
at Precision Neuroscience
GlobeNewswire
May 1, 2025
John Woock
Commercial Operations Lead
From
Head of Commercial Operations
at Axonics (acquired by Boston Scientific)
To
Chief Business Officer
at Precision Neuroscience
GlobeNewswire
Dec 22, 2024
David McMullen
Director, Office of Neurological and Physical Medicine Devices
From
Director, Office of Neurological and Physical Medicine Devices
at U.S. Food and Drug Administration
To
Head of Medical Affairs
at Neuralink
Bloomberg
May 1, 2021
Max Hodak
President
From
President & Co-founder
at Neuralink
To
Founder & CEO
at Science Corporation
TechCrunch

Catalysts

Conferences

Major industry dates · soonest first

Jun 30, 2026Neurotech Leaders Forum Europe — Leuven
Jul 26, 2026IEEE EMBC 2026 — Toronto
Jul 30, 20262026 NYC Neuromodulation Conference
Sep 14, 202610th Graz BCI Conference 2026

Venture Stages

1

Seed

Merge Labs$252M
Elemind$12M
Subsense$10M
Augmental$4M
Emotiv$3.9M
Cognixion$1.8M
OpenBCI$1.8M
Cogwear

2

Series A

Series A

Axoft$55M
Neurable$35M
Paradromics$33M
Phantom Neuro$19M
Motif Neurotech$18.8M
Neuroelectrics$17.5M
NextSense$16M
Forest Neurotech$14M
Arctop$10M
Flow Neuroscience$9.3M
Neurosity$5.0M
BIOS Health
Galvani Bioelectronics

3

Series B

Series B

BrainCo$286M
INBRAIN Neuroelectronics$50M

4

Series C

Series C

Science Corporation$230M
Precision Neuroscience$102M
Kernel$53M

5

Series D

Series D

Neuralink$650M
Synchron$200M
MindMaze$125M

6

Public & Acquired

Public & Acquired

Ceribell$207.3M
Saluda Medical$150M
NeuroPace$105.2M
ONWARD Medical$89.6M
Abbott
Boston Scientific
Medtronic

Valuations

Sized by valuation · area is proportional to market value

Zoom

Public caps as of Jun 17, 2026

Boston Scientific

Public · real-time market capPrivate · last-round valuation

6 companies without valuation on file

Funding & analysis

AI Analysis

BCI's capital cycle matures: Neuralink's $650M Series E leads five $200M+ checks since mid-2025.

Updated Jun 2026 · 71 rounds

Company

15

16

17

18

19

20

21

22

23

24

25

26

Total Raised

Bottlenecks

Multiple bets

Chronic biocompatibility and signal stability

Implanted electrodes trigger a foreign-body immune response — microglia and astrocytes encapsulate the device in a glial scar that progressively insulates it from nearby neurons. Most intracortical arrays show significant signal degradation within 6–12 months; the longest continuously recording BCI has operated for ~7 years, well short of a device lifetime patients need. Stiffness mismatch between silicon/metal electrodes and soft brain tissue accelerates the mechanical micromotion that kicks off the cascade.

Approaches in flight

Chronic biocompatibility and signal stability

▸ Ultra-soft and compliant materials

Axoft is developing hydrogel-like electrodes whose elastic modulus matches brain tissue, aiming to suppress the foreign-body response at its root. Forest Neurotech and INBRAIN Neuroelectronics are pursuing flexible graphene and polymer substrates for the same reason.

▸ Bio-inspired and hybrid interfaces

Academic labs (e.g., the Bhanu Bhanu group at UCLA, Rice University's Kemere lab) are coating electrodes with neural cell precursors or conductive hydrogels to blur the device–tissue boundary. Blackrock Neurotech released updated microelectrode arrays in early 2025 that incorporate surface coatings to reduce reactive gliosis.

▸ Endovascular routing to avoid parenchymal trauma

Synchron's Stentrode occupies cerebral blood vessels rather than brain tissue, sidestepping the glial-scar problem entirely — at the cost of recording channel count and proximity to neurons.

Multiple bets

Wireless power and high-bandwidth telemetry through the skull

A fully implanted BCI must transmit raw neural data — potentially terabytes per hour at high channel counts — through skull and scalp without a percutaneous lead, while receiving enough power wirelessly to keep the implant alive 24/7. Electromagnetic losses in tissue, antenna miniaturization limits, and SAR (specific absorption rate) safety ceilings create a hard tradeoff: more bandwidth requires more power, which risks tissue heating. Current FDA-cleared systems resolve this by processing on-chip and transmitting only spike-sorted data, sacrificing information.

Approaches in flight

Wireless power and high-bandwidth telemetry through the skull

▸ On-device compression and spike sorting

Neuralink's N1 chip and Blackrock Neurotech's Ceriplex-i perform signal processing in situ, reducing wireless payload to decoded events rather than raw voltages. This trades bandwidth for power efficiency but discards sub-threshold neural dynamics.

▸ Ultra-wideband (UWB) high-rate links

Paradromics, in collaboration with the University of Michigan, demonstrated a 100 Mbps UWB relay link in a 2025 first-in-human intraoperative recording — roughly 100× the throughput of competing Bluetooth-based systems. Whether UWB clears SAR limits at chronic implant distances remains unresolved.

▸ Near-field inductive power + optical data

Academic groups (MIT, Caltech) are exploring near-infrared optical transcutaneous links for high-bandwidth data, paired with resonant inductive coils for power. No commercial product has reached human trials on this architecture.

Decade away

Neural decoding that generalizes across sessions and users

Neural population codes shift day-to-day — electrodes drift relative to neurons, plasticity remaps representations, and signal statistics change with mental state and fatigue. Most current BCI decoders require daily or session-by-session recalibration by a trained clinician, making home use impractical. Generalizing a decoder trained on one patient to another is harder still, as the cortical maps and implant placements differ. Speech BCIs face the additional challenge that imagined speech lacks the articulatory-kinematic ground truth used to train production-based decoders.

Approaches in flight

Neural decoding that generalizes across sessions and users

▸ Adaptive and continual learning decoders

Neuralink and Precision Neuroscience have published on closed-loop decoder recalibration that runs autonomously between sessions. Stanford's BrainGate consortium has demonstrated adaptive RNN decoders that track neural drift over months without user intervention.

▸ Foundation models for neural signals

Groups at Google DeepMind, UC San Diego, and several academic labs are training large models on pooled multi-patient ECoG and intracortical datasets, seeking representations that transfer across individuals — analogous to what BERT-style pretraining did for NLP.

▸ Imagined-speech decoding from motor cortex

A 2025 Cell paper demonstrated that inner speech is robustly represented in motor cortex and can be decoded in real time, offering a path for patients with complete speech loss. Precision Neuroscience's high-density Layer 7 array provides the electrode resolution needed to test this clinically.

Decade away

Scaling to millions of simultaneously recorded neurons

The brain contains ~86 billion neurons; current state-of-the-art implants record from hundreds to low thousands of single units simultaneously. Scaling by orders of magnitude is required to decode complex cognitive states, continuous speech, or dexterous hand control at natural bandwidth. Each added channel multiplies data throughput, power, heat dissipation, and surgical complexity — engineering constraints that compound nonlinearly.

Approaches in flight

Scaling to millions of simultaneously recorded neurons

▸ High-density thin-film arrays

Precision Neuroscience's Layer 7 delivers 1,024 electrodes in a sub-millimeter slit; the company filed a PMA in 2025 for chronic use. Forest Neurotech is developing a distributed intracortical mesh targeting 10,000+ sites.

▸ Distributed modular implants

Paradromics is pursuing a modular "neural bus" architecture where many small electrode bundles connect to a single external processor, avoiding the single-point thermal ceiling. Neuralink's thread-based approach with the R1 robotic inserter is designed to add threads incrementally.

▸ Non-invasive high-density sensing

Kernel's Flow helmet uses time-domain fNIRS across 52 modules to sample hemodynamic correlates of population activity non-invasively. Temporal resolution (~1 s) and spatial resolution (~1 cm) remain far below intracortical recording, but the approach scales without surgery.

Multiple bets

Closed-loop bidirectional stimulation without recording artifacts

Therapeutic BCIs must both read neural signals and write back stimulation — in DBS for Parkinson's, spinal cord stimulation for paralysis, or direct cortical feedback for sensory restoration. The core problem is that stimulation pulses saturate the same amplifiers used to record, creating blanking windows during which neural state is invisible. Designing circuits that can sense and stimulate simultaneously, at the same electrode site, is an unsolved mixed-signal engineering and electrode-materials challenge.

Approaches in flight

Closed-loop bidirectional stimulation without recording artifacts

▸ Stimulation artifact cancellation in ASIC

Medtronic's Percept PC DBS system uses an on-chip artifact-rejection architecture for local field potential recording during stimulation. ONWARD Medical's ARC-BCI pairs cortical recording with epidural spinal cord stimulation, requiring careful temporal interleaving to suppress cross-talk.

▸ Novel electrode geometries to separate record/stim sites

Ripple Neuro and Blackrock Neurotech offer research platforms with spatially separated recording and stimulation contacts. Academic groups at Caltech and ETH Zurich are exploring micro-ring electrode designs that minimize charge injection at recording sites.

▸ Analog front-end blanking with fast recovery

BIOS Health and several academic VLSI labs are developing sub-microsecond blanking circuits that clamp amplifier inputs during stimulation pulses and recover in under 100 µs, small enough to preserve inter-pulse neural dynamics. No commercial implant has fully solved recovery at high stimulation frequencies.

Decade away

Establishing a chronic-implant regulatory pathway

No fully implanted BCI has received FDA Premarket Approval for chronic use; current cleared devices are limited to 30 days (Precision Neuroscience's 510(k)) or early-feasibility IDE status. The FDA lacks established evidentiary standards for what constitutes sufficient safety data — how many patient-years, which adverse event rates, what functional endpoints — to approve a chronic neural interface for communication or motor restoration. This regulatory ambiguity creates planning risk for the entire field, not just individual companies.

Approaches in flight

Establishing a chronic-implant regulatory pathway

▸ PMA via pivotal randomized trial

Precision Neuroscience filed what may be the first BCI PMA in 2025, leveraging its 1,024-channel Layer 7 array. Synchron is in active discussions with FDA about endpoints for a multicenter pivotal trial following its completed COMMAND feasibility study.

▸ Breakthrough Device Designation to accelerate review

Neuralink received a Breakthrough Device Designation for speech restoration in May 2025. CorTec received its own Breakthrough Device Designation for stroke motor rehabilitation in April 2026 — the first such designation globally for a BCI targeting stroke. These designations compress FDA review timelines but do not lower evidentiary bars.

▸ Adaptive trial designs and surrogate endpoints

Academic consortia including BrainGate and the NIH Brain Initiative are advocating for surrogate functional endpoints (typing speed, cursor accuracy, activities of daily living scores) that can be measured in small feasibility cohorts and extrapolated to safety-benefit approvals.

Investment Theses

Thesis

Medical approval is the only credible path to consumer

The only sustainable route to a mass-market neural interface runs through the FDA. Companies that secure PMA for a clinical indication — ALS communication, paralysis motor restoration — acquire safety data, surgical infrastructure, and regulatory standing that no consumer-first player can shortcut. The TAM isn't the ~500k severely paralyzed patients in the US; it's the tens of millions of mild motor and cognitive impairment patients, and eventually a consumer enhancement market, accessible only after the clinical moat is built.

Counter-thesis

Medical approval is the only credible path to consumer

The FDA timeline for chronic BCI approval is 5-10+ years from first-in-human, with no guarantee of approval. Clinical markets are small and reimbursement uncertain — Medicare and private payers have no BCI coverage policy. Companies that survive on grant + VC funding while burning toward PMA may run out of runway before the regulatory path clears, leaving the consumer market to non-invasive players who reach scale first without FDA complexity.

Thesis

Minimal surgical footprint captures the broadest patient population

Open craniotomy is a hard sell to neurologists and patients for a communication device — even when the alternative is permanent silence. The thesis: the BCI company that can implant through a vascular catheter, a slit craniotomy, or a burr hole captures the neurology referral funnel that will never accept elective open-brain surgery. Lower surgical risk expands the addressable patient pool by an order of magnitude and earns neurology champions rather than neurosurgery champions, which is the faster referral path.

Counter-thesis

Minimal surgical footprint captures the broadest patient population

Minimally invasive access trades surgical risk for signal quality. Endovascular signals are far noisier and lower-bandwidth than intracortical recordings; slit-craniotomy surface arrays sample population LFP rather than single units. If the winning applications require high channel counts and single-neuron resolution — dexterous hand control, full-vocabulary speech synthesis — minimally invasive approaches may hit a hard performance ceiling that forces patients back to open surgery.

Thesis

Neural data is the defensible moat, not the electrode

Electrodes and ASICs will commoditize — the lasting asset is proprietary neural datasets large enough to train decoders that generalize across patients and sessions. The company that accumulates the most patient-hours of labeled intracortical data builds decoder models that no one else can replicate, creating a platform layer analogous to what OpenAI's training corpus did for LLMs. Medical partners (surgical systems vendors, pharma, neuromodulation companies) will pay for access to this data layer.

Counter-thesis

Neural data is the defensible moat, not the electrode

Neural data collected under FDA IDE is subject to strict de-identification and consent constraints that limit commercial use. Patient cohorts are tiny by ML standards — tens to low hundreds of subjects — and cross-patient generalization in neural decoding has proved far harder than in language or vision. The data moat may never be deep enough to matter before hardware commoditization erodes margins anyway.

Thesis

Spinal and peripheral nerve interfaces beat cortical for motor restoration

Cortical BCIs route around the problem but not through it — they bypass the damaged spinal cord to drive external devices, leaving the body's own motor infrastructure idle. The more efficient bet is to reconnect cortex to spinal cord and peripheral nerve via electrical bridges that restore volitional movement through the patient's own limbs. Epidural spinal cord stimulation combined with cortical decoding targets the same patient population at lower surgical risk and with a demonstrated reimbursement pathway (SCS is already covered).

Counter-thesis

Spinal and peripheral nerve interfaces beat cortical for motor restoration

Spinal and peripheral approaches require intact downstream motor pathways — they cannot help patients with complete spinal injuries or degenerative upper motor neuron disease (ALS). The cortical BCI market, though smaller today, is the only option for the most severe injuries and degenerative diseases, which are also the highest-willingness-to-pay segments. Peripheral nerve and SCS players also compete directly against well-capitalized established neuromodulation incumbents (Medtronic, Abbott, Boston Scientific) who own the surgeon relationships.

Thesis

Non-invasive EEG/fNIRS captures consumer and enterprise wellness before implants scale

High-bandwidth implants will take a decade to reach consumer approval. Meanwhile, dry-electrode EEG and fNIRS headsets are improving fast enough — aided by ML decoding and miniaturized optics — to deliver useful passive state monitoring (focus, fatigue, stress) and limited active control to enterprise wellness, gaming, and accessibility markets. The consumer BCI revenue opportunity in the next 5 years belongs to non-invasive players, not implant companies.

Counter-thesis

Non-invasive EEG/fNIRS captures consumer and enterprise wellness before implants scale

Non-invasive signals are fundamentally bandwidth-limited by skull and scalp attenuation — no amount of ML closes the gap with intracortical recording for high-DOF control. Consumer EEG products have been "almost ready" for 15 years without achieving meaningful retention or revenue at scale. Wellness BCI may be a feature, not a company — absorbed into AirPods, smart glasses, or fitness trackers by Apple, Meta, or Google rather than generating independent platform value.

Top 10

Investors

By tracked rounds led

01Khosla Ventures5 rounds
02Boston Scientific3 rounds
03Prime Movers Lab3 rounds
04Founders Fund2 rounds

Books

Relevancy
Most recent

Jonathan R. Wolpaw and Elizabeth Winter Wolpaw · 2012
Brain-Computer Interfaces: Principles and Practice
This is the foundational engineering text for the whole sector — the signal-processing and decoding pipeline it formalizes is the same one Blackrock Neurotech and Synchron build their clinical systems on, and its noninvasive EEG chapters underpin consumer players like Emotiv and OpenBCI.
Buy Read reviews
Eric R. Kandel, John D. Koester, Sarah H. Mack, and Steven A. Siegelbaum · 2021
Principles of Neural Science
It is the canonical reference for the neurophysiology every implant must respect — the motor-cortex and sensorimotor chapters describe exactly the signals Neuralink and Paradromics decode for movement, and the ones Precision Neuroscience and Synchron target for restoration.
Buy Read reviews
Peter Dayan and L. F. Abbott · 2005
Theoretical Neuroscience: Computational and Mathematical Modeling of Neural Systems
The population-decoding and neural-coding theory it formalizes is the mathematical core of every cortical BCI — it is the framework behind how Neuralink and Blackrock Neurotech turn multi-electrode spike data into cursor and limb control, and how Synchron extracts intent from vascular-surface recordings.
Buy Read reviews
Nita A. Farahany · 2023
The Battle for Your Brain: Defending the Right to Think Freely in the Age of Neurotechnology
The governance debate that every BCI company will eventually face is already mapped here; Farahany's neurorights framework is the vocabulary regulators, ethicists, and investors now use when they ask hard questions about what implants can and cannot do.
Buy Read reviews
Miguel Nicolelis · 2011
Beyond Boundaries: The New Neuroscience of Connecting Brains with Machines—and How It Will Change Our Lives
One of the founding scientists of modern BCI research tells the origin story of the field from the inside; the experiments described here directly seeded the company formation wave the sector is now living through.
Buy Read reviews
Sebastian Seung · 2012
Connectome: How the Brain's Wiring Makes Us Who We Are
The scientific foundation for understanding why high-channel-count implants matter: the more neurons you can record simultaneously, the closer you get to the circuit-level computation BCIs need to read and write.
Buy Read reviews
Matthew Cobb · 2020
The Idea of the Brain: The Past and Future of Neuroscience
Essential critical thinking for BCI builders: Cobb's thesis is that every generation mistakes its current metaphor for truth; understanding that history guards against over-confidence in today's neural decoding frameworks.
Buy Read reviews
Michio Kaku · 2014
The Future of the Mind: The Scientific Quest to Understand, Enhance, and Empower the Mind
A broad map of the long-arc BCI research agenda — telepathy, brain-to-brain communication, cognitive enhancement — useful for situating any company's near-term clinical work inside the larger technological trajectory.
Buy Read reviews
Jill Bolte Taylor · 2008
My Stroke of Insight: A Brain Scientist's Personal Journey
A first-person account of the exact neural systems BCI companies are targeting for restoration — reading it grounds the engineering problem in lived human experience in a way no data sheet can.
Buy Read reviews

·

·

·

·

·

© 2026 fobi

Theme

Send feedback

Goes straight to my inbox. No auto-replies, no tickets.

What's this about?

General feedbackSomething's brokenFeature ideaContent / data issue

Feedback

Email (optional — only if you want a reply)

Website

Reviewed weekly.

Sentiment · 7d

0

Positive

0

Neutral

0

Negative

Hot company · 7d

—

no coverage yet

Most patents filed · 12mo

no patents in window

Most raised · all-time

01Neuralink$1.2B
02Saluda Medical$530M
03Science Corporation$490M

Closed-loop adaptive deep brain stimulation improves gait symmetry and reduces falls in Parkinson's patients.

Neuroscience News ↗

Jun 2·Regulation·negative

STAT+: Online care is caught in the crossfire as states crack down on corporate medicine

State corporate practice of medicine laws create operational constraints for telehealth platforms, forcing companies to work through physician-owned practices as intermediaries.

Jun 1·Research·positive

DBS Remodels White Matter Paths to Reverse Depression

Study demonstrates deep brain stimulation remodels white matter pathways and alters neural network communication in depression treatment.

Neuroscience News ↗

Jun 1·Research·neutral

AI System Successfully Decodes and Tracks Pain via EEG

Research demonstrates an AI framework that classifies pain intensity from EEG signals objectively.

Neuroscience News ↗

May 24·Research·neutral

System Boosts Speech Volume Based on Brain Signals

Auditory attention decoding from brain signals enables real-time hearing aid volume control, improving speech comprehension in noisy settings.

IEEE Spectrum (Biomedical) ↗

Oct 14, 2026World Congress on Neurorehabilitation (WCNR) 2026

Nov 14, 2026Society for Neuroscience — Neuroscience 2026 (SfN)

Earnings Calls

Public roster companies · forecast from SEC filings

Jul 17, 2026· rumoredAbbott — Q2 2026 earnings
Jul 22, 2026· rumoredBoston Scientific — Q2 2026 earnings
Aug 10, 2026· rumoredCeribell — Q2 2026 earnings
Aug 11, 2026· rumoredNeuroPace — Q2 2026 earnings
Sep 2, 2026· rumoredMedtronic — Q3 2026 earnings

Predictions

Public claims with deadlines

Dec 31, 2026· Elon Musk (Neuralink) @ NeuralinkNeuralink will begin high-volume production of its brain-computer interface and shift to an almost entirely automated surgical procedure in 2026, with threads placed through the dura
Dec 31, 2026· Elon Musk (Neuralink) @ NeuralinkNeuralink will perform the first human implant of its Blindsight visual-cortex device in 2026, pending regulatory approval
Dec 31, 2026· Science Corporation @ Science CorporationScience Corporation will launch its PRIMA retinal implant commercially in Europe before the end of 2026, becoming the first BCI company with a vision-restoration product on the market
Dec 31, 2026· Synchron @ SynchronSynchron will run the pivotal trial of its Stentrode BCI in 2026 — the study it must clear before filing the first-ever FDA premarket approval for an implantable brain-computer interface

Policy & Courts

Hearings · rulings · statutory deadlines

Nothing on the calendar yet.

Round sizes
Top-end checks carry an order of magnitude more zeroes than 2022's $6M-median year: Neuralink's $650M Series E, Boston Scientific's $533M Nalu acquisition, BrainCo's $286M at $1.3B, Science Corporation's $230M Series C. The early end still functions — Subsense's $10M seed and NextSense's $16M Series A both closed in late 2025.
Stage mix
Unusually for a maturing frontier sector, the stage pyramid still has a base: since 2025, four Series As and two seeds sit under two growth rounds, Synchron's $200M Series D the deepest. M&A is the live exit — Boston Scientific bought Nalu for $533M in October 2025, eighteen months after Tether's $200M Blackrock Neurotech deal.
Lead investors
Khosla Ventures owns the category with five leads, including Science Corporation's $230M Series C in March 2026. Generalist giants arrived in 2025–26: Sequoia and ARK on Neuralink, Lightspeed co-leading Science, IDG Capital pricing BrainCo at $1.3B. Prime Movers Lab, a three-time lead, has been silent since 2023.

05Golden Falcon Capital2 rounds

06re.Mind Capital2 rounds

07The Rise Fund2 rounds

08AlbaCore Capital Group1 round

09Ally Bridge Group1 round

10AME Cloud Ventures1 round

Publications

By relevant articles ingested

01Neuroscience News3 articles
02IEEE Spectrum (Biomedical)1 article
03MIT Technology Review1 article
04STAT News1 article

Conferences

Where the sector convenes

01SfN NeuroscienceSociety for Neuroscience Annual Meeting — 30,000+ scientists across 80 countries; largest neuroscience conference in the world
02IBCI MeetingInternational Brain-Computer Interface Meeting — flagship BCI Society conference; held biennially
03IEEE EMBCIEEE Engineering in Medicine and Biology Conference — premier biomedical engineering venue with deep neural engineering and BCI tracks
04Graz BCI ConferenceInternational Brain-Computer Interface Conference at TU Graz — the specialist academic BCI conference, held biennially
05NeurIPSConference on Neural Information Processing Systems — hosts BCI, neural decoding, and brain-inspired AI workshops
06NeuroTech WorldIndustry-focused neurotechnology summit bridging BCI research and commercial applications
07BCI ConventionAnnual BCI industry conference and expo featuring academic, clinical, and commercial BCI presentations
08CES Digital HealthCES neurotechnology and digital health track — major consumer and clinical BCI product launches

University labs

Talent + spinout pipeline

01UCSF Chang LabEdward Chang's speech neuroprosthetics lab — leading clinical BCI trials restoring communication for paralyzed patients
02Stanford Neural Prosthetics LabShenoy lab — decoding motor cortex signals for high-performance BCI; key academic home for Neuralink-adjacent research
03Wyss Center GenevaNot-for-profit neurotechnology foundation developing the ABILITY fully implantable wireless BCI
04Johns Hopkins APL Neural InterfacesApplied Physics Laboratory's neural interface program — modular prosthetic limbs, non-invasive cortical recording
05CMU Neural EngineeringCarnegie Mellon biomedical engineering — noninvasive BCI using EEG and neural signal processing
06Brown Carney InstituteHome of BrainGate — pioneering intracortical BCI program with the longest human trial history in the field
07Caltech Andersen LabRichard Andersen's lab — posterior parietal cortex BCI for intention decoding and prosthetic control
08University of Pittsburgh UPMC BCI LabGaunt / Collinger labs — clinical BCI trials including first closed-loop sensory feedback in a human
09ETH Zurich Neural Control of MovementRiener lab — neuroprosthetics, exoskeletons, and spinal cord stimulation for motor restoration
10École Polytechnique Fédérale de Lausanne (EPFL) Microcircuit LabMarkram lab and NeuroRestore group — brain simulation and epidural electrical stimulation for paralysis

Founding

50% off

$5

/month

91 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access